Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral genome and has been a prime target for drug discovery efforts. Here, we report on the further development of tetracyclic indole inhibitors, binding to an allosteric site on the thumb domain. Structure-activity relationship (SAR) studies around an indolo-benzoxazocine scaffold led to the identification of compound 33 (MK-3281), an inhibitor with good potency in the HCV subgenomic replication assay and attractive molecular properties suitable for a clinical candidate. The compound caused a consistent decrease in viremia in vivo using the chimeric mouse model of HCV infection.

Discovery of (7R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B Polymerase / F. Narjes, B. Crescenzi, M. Ferrara, J. Habermann, S. Colarusso, M. Del Rosario Rico Ferreira, I. Stansfield, A.C. Mackay, I. Conte, C. Ercolani, S. Zaramella, M. Palumbi, P. Meuleman, G. Leroux-Roels, C. Giuliano, F. Fiore, S. Di Marco, P. Baiocco, U. Koch, G. Migliaccio, S. Altamura, R. Laufer, R. De Francesco, M. Rowley. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 54:1(2011), pp. 289-301. [10.1021/jm1013105]

Discovery of (7R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B Polymerase

R. De Francesco;
2011

Abstract

Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral genome and has been a prime target for drug discovery efforts. Here, we report on the further development of tetracyclic indole inhibitors, binding to an allosteric site on the thumb domain. Structure-activity relationship (SAR) studies around an indolo-benzoxazocine scaffold led to the identification of compound 33 (MK-3281), an inhibitor with good potency in the HCV subgenomic replication assay and attractive molecular properties suitable for a clinical candidate. The compound caused a consistent decrease in viremia in vivo using the chimeric mouse model of HCV infection.
Dependent RNA-polymerase; chimeric human livers; de-novo initiation; UPA-scid mouse; allosteric inhibitors; nonnucleoside inhibitors; HCVNS5B polymerase; in-vivo; benzimidazole derivates; antiviral activity
Settore BIO/10 - Biochimica
Settore BIO/13 - Biologia Applicata
Settore BIO/14 - Farmacologia
2011
Article (author)
File in questo prodotto:
File Dimensione Formato  
jm1013105.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.08 MB
Formato Adobe PDF
2.08 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/634731
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 65
  • ???jsp.display-item.citation.isi??? 61
social impact